Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ICAD

ICAD - Icad Inc Stock Price, Fair Value and News

$19.72+0.10 (+0.51%)
Market Closed

6/100

ICAD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

6/100

ICAD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ICAD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ICAD Price Action

Last 7 days

-2.6%

Last 30 days

-8.9%

Last 90 days

-5.4%

Trailing 12 Months

-3.2%

ICAD RSI Chart

ICAD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ICAD Valuation

Market Cap

573.1M

Price/Earnings (Trailing)

-115.62

Price/Sales (Trailing)

30.95

EV/EBITDA

-119.3

Price/Free Cashflow

-218.26

ICAD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ICAD Fundamentals

ICAD Revenue

ICAD Earnings

ICAD Profitability

Free Cashflow Yield

-0.46%

ICAD Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202519.5M000
202417.9M18.8M18.9M19.6M
202318.8M15.4M15.1M17.3M
202232.5M32.3M27.3M21.9M
202131.8M34.0M36.3M33.6M
202031.1M29.4M28.6M29.7M
201926.1M27.2M28.9M31.3M
201827.6M27.4M26.6M25.6M
201727.1M26.1M27.1M28.1M
201634.4M30.6M27.0M26.3M
201548.6M50.1M47.1M41.6M
201433.7M35.6M39.9M43.9M
201329.9M31.6M31.8M33.1M
201227.7M26.9M27.1M28.3M
201125.4M25.9M28.4M28.7M
2010026.9M25.8M24.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Icad Inc

ICAD
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
 CEO
 WEBSITEicadmed.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES108

Icad Inc Frequently Asked Questions

ICAD is the stock ticker symbol of Icad Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Icad Inc is 573.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, ICAD's PE ratio (Price to Earnings) is -115.62 and Price to Sales (PS) ratio is 30.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICAD PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Icad Inc has provided -0.117 (multiply by 100 for percentage) rate of return.